JP2022501441A5 - - Google Patents
Info
- Publication number
- JP2022501441A5 JP2022501441A5 JP2021540786A JP2021540786A JP2022501441A5 JP 2022501441 A5 JP2022501441 A5 JP 2022501441A5 JP 2021540786 A JP2021540786 A JP 2021540786A JP 2021540786 A JP2021540786 A JP 2021540786A JP 2022501441 A5 JP2022501441 A5 JP 2022501441A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- composition according
- therapeutically effective
- cancer
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024135623A JP2024178159A (ja) | 2018-09-21 | 2024-08-15 | 癌を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734649P | 2018-09-21 | 2018-09-21 | |
| US62/734,649 | 2018-09-21 | ||
| PCT/US2019/052161 WO2020061458A1 (en) | 2018-09-21 | 2019-09-20 | Methods of treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135623A Division JP2024178159A (ja) | 2018-09-21 | 2024-08-15 | 癌を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501441A JP2022501441A (ja) | 2022-01-06 |
| JP2022501441A5 true JP2022501441A5 (https=) | 2022-09-29 |
| JPWO2020061458A5 JPWO2020061458A5 (https=) | 2022-09-29 |
Family
ID=69887889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540786A Withdrawn JP2022501441A (ja) | 2018-09-21 | 2019-09-20 | 癌を治療する方法 |
| JP2024135623A Pending JP2024178159A (ja) | 2018-09-21 | 2024-08-15 | 癌を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135623A Pending JP2024178159A (ja) | 2018-09-21 | 2024-08-15 | 癌を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220125957A1 (https=) |
| EP (1) | EP3852816A4 (https=) |
| JP (2) | JP2022501441A (https=) |
| KR (1) | KR20210095620A (https=) |
| CN (4) | CN113164631A (https=) |
| AU (2) | AU2019345320B2 (https=) |
| CA (1) | CA3112806A1 (https=) |
| IL (2) | IL281600B2 (https=) |
| WO (1) | WO2020061458A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| US12208102B2 (en) | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| US11129912B1 (en) | 2020-07-13 | 2021-09-28 | POINT Biopharma Inc. | Radiopharmaceutical and methods |
| KR20240004205A (ko) | 2020-07-13 | 2024-01-11 | 포인트 바이오파마 인코포레이티드 | 방사성의약 및 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
| LT4095130T (lt) * | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| IL237525A (en) * | 2015-03-03 | 2017-05-29 | Shalom Eli | Method for labeling a prostate-specific membrane antigen with a radioactive isotope |
| WO2017117687A1 (en) * | 2016-01-10 | 2017-07-13 | British Columbia Cancer Agency Branch | 18/19f-labelled compounds which target the prostate specific membrane antigen |
| WO2018108287A1 (en) * | 2016-12-15 | 2018-06-21 | The European Atomic Energy Community (Euratom), Represented By The European Commission | Treatment of pmsa expressing cancers |
| SG11202005511VA (en) * | 2017-12-13 | 2020-07-29 | Sciencons AS | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |
-
2019
- 2019-09-20 CA CA3112806A patent/CA3112806A1/en active Pending
- 2019-09-20 IL IL281600A patent/IL281600B2/en unknown
- 2019-09-20 WO PCT/US2019/052161 patent/WO2020061458A1/en not_active Ceased
- 2019-09-20 JP JP2021540786A patent/JP2022501441A/ja not_active Withdrawn
- 2019-09-20 CN CN201980077048.3A patent/CN113164631A/zh active Pending
- 2019-09-20 EP EP19863079.0A patent/EP3852816A4/en active Pending
- 2019-09-20 KR KR1020217011840A patent/KR20210095620A/ko not_active Ceased
- 2019-09-20 CN CN202510991493.8A patent/CN121154858A/zh active Pending
- 2019-09-20 AU AU2019345320A patent/AU2019345320B2/en active Active
- 2019-09-20 CN CN202510991495.7A patent/CN121130116A/zh active Pending
- 2019-09-20 US US17/277,803 patent/US20220125957A1/en active Pending
- 2019-09-20 CN CN202510991492.3A patent/CN121338051A/zh active Pending
-
2024
- 2024-08-15 JP JP2024135623A patent/JP2024178159A/ja active Pending
-
2025
- 2025-10-15 IL IL323981A patent/IL323981A/en unknown
-
2026
- 2026-03-11 AU AU2026201845A patent/AU2026201845A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501441A5 (https=) | ||
| JP2024178159A5 (https=) | ||
| Wang et al. | Current diagnosis and management of small-cell lung cancer | |
| Liu et al. | 99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma | |
| Finn et al. | Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma | |
| Nagaraju et al. | Cyclooxygenase‐2 in gastrointestinal malignancies | |
| RU2015121367A (ru) | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний | |
| Nemes et al. | Gastrointestinal stromal tumor (GIST) associated with synchronous colon adenocarcinoma-a case report | |
| JP2021502415A5 (https=) | ||
| JP2019527740A5 (https=) | ||
| Hsieh et al. | Enhanced antitumour response of gold nanostar-mediated photothermal therapy in combination with immunotherapy in a mouse model of colon carcinoma | |
| JPWO2020061458A5 (https=) | ||
| Zhang et al. | 18F-FAPI-42 PET/CT enhances the diagnostic efficacy for peritoneal metastasis of colorectal cancer and guides treatment decisions: an original retrospective study | |
| Cao et al. | Analysis of the clinicopathological features and prognostic factors in 734 cases of Chinese Hui and Han patients with adenocarcinoma of the esophagogastric junction | |
| CA2483826A1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| Neves et al. | Extended survival after complete pathological response in metastatic pancreatic ductal adenocarcinoma following induction chemotherapy, chemoradiotherapy, and a novel immunotherapy agent, IMM-101 | |
| RU2021111125A (ru) | Способы лечения рака | |
| JPWO2021168028A5 (https=) | ||
| JP2020510009A5 (https=) | ||
| Liu et al. | Case report: A case study of neoadjuvant immunochemotherapy for locally advanced esophageal squamous carcinoma | |
| Liu et al. | Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports | |
| Masamatti et al. | Gastroesophageal junction adenocarcinoma metastasizing to gingiva | |
| FANG et al. | Research status and treatment strategies of maintenance therapy for metastatic colorectal cancer | |
| YU et al. | TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION COMBINED WITH MOLECULAR TARGETED THERAPY FOR A PATIENT WITH HEPATOCELLULAR CARCINOMA WITH INTRAHEPATIC METASTASIS AND MAIN PORTAL VEIN TUMOR THROMBUS: A CASE REPORT AND LITERATURE REVIEW | |
| RU2015142258A (ru) | Противоопухолевая композиция, включающая pi3k бета-селективный ингибитор и pi3k альфа-селективный ингибитор |